There is a large body of evidence describing the utility of antidiabetes agents in people with chronic kidney disease (CKD). Clinical decisions should take into account the pharmacokinetic variability and potential adverse events seen when these agents are used in renally impaired patients. In this article, the authors review the literature and summarise which antidiabetes agents are safe, with dose reductions if necessary, in people with CKD.
|Original language||English (US)|
|Number of pages||6|
|Journal||Journal of Diabetes Nursing|
|Publication status||Published - 2016|
All Science Journal Classification (ASJC) codes
- Endocrinology, Diabetes and Metabolism
- Advanced and Specialized Nursing